AstraZeneca ((AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca has completed a Phase III study titled A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants With Active Systemic Lupus Erythematosus. The study aimed to assess the efficacy and safety of an intravenous treatment regimen of anifrolumab compared to a placebo in Asian patients with active systemic lupus erythematosus (SLE), a chronic autoimmune disease.
The intervention tested was anifrolumab, a biological treatment administered via intravenous infusion. This treatment is designed to help manage moderate to severe SLE by targeting specific immune pathways involved in the disease.
The study was interventional, with participants randomly assigned to either the anifrolumab or placebo group. It followed a parallel intervention model with quadruple masking to ensure unbiased results. The primary goal was treatment efficacy.
The study began on September 13, 2021, and was completed with the last update submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and understanding its timeline within the clinical research landscape.
The completion of this study could influence AstraZeneca’s stock performance positively, as successful results may enhance investor confidence and market position. It also positions AstraZeneca competitively within the pharmaceutical industry, particularly in the autoimmune treatment sector.
The study is now completed, with further details available on the ClinicalTrials portal.